公开(公告)号：US20230374029A1

公开(公告)日：2023-11-23

申请号：US18004313

申请日：2021-07-06

Applicant: Novartis AG

Inventor： Zhongbo FEI ,  Huanqing JIA ,  Wei LI ,  Jianhua WANG ,  Huangchao YU

IPC: C07D491/107

CPC classification number: C07D491/107

Abstract: The present invention relates to a method for the manufacture of a compound of Formula I or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, said method comprising reacting a compound of the formula II with a compound of the formula III according to the following reaction scheme: wherein LG, A, n, m and p are as defined in the Summary of the Invention, said manufacture including the manufacture and use of a compound of the formula VI; wherein R1 is a secondary amino protecting group and R5 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl or unsubstituted or substituted aryl.

公开(公告)号：US20240245694A1

公开(公告)日：2024-07-25

申请号：US18483651

申请日：2023-10-10

Applicant: Novartis AG

Inventor： Vincent BORDAS ,  Markus FUREGATI ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Ziyue HONG ,  Fabio LIMA ,  Fatma LIMAM ,  Henrik MOEBITZ ,  Sandro NOCITO ,  Niko SCHMIEDEBERG ,  Joseph SCHOEPFER ,  Ross Sinclair STRANG ,  Frédéric ZECRI ,  Huangchao YU ,  Yong ZHANG ,  Xinkan YANG ,  Sisi ZHANG ,  Wei LI

IPC: A61K31/5377 ,  A61K31/519 ,  C07D487/14 ,  C07D519/00

CPC classification number: A61K31/5377 ,  A61K31/519 ,  C07D487/14 ,  C07D519/00

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I):




wherein R1, R2, R3, x, R4, R5, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

公开(公告)号：US20210299100A1

公开(公告)日：2021-09-30

申请号：US17201268

申请日：2021-03-15

Applicant: Novartis AG

Inventor： Vincent BORDAS ,  Cara BROCKLEHURST ,  Patrick CHENE ,  Zhongbo FEI ,  Pascal FURET ,  Vito GUAGNANO ,  Patricia IMBACH-WEESE ,  Joerg KALLEN ,  Mickael LE DOUGET ,  Jialiang LI ,  Wei LI ,  Edwige Liliane Jeanne LORTHIOIS ,  Joseph McKENNA ,  Bahaa SALEM ,  Tobias SCHMELZLE ,  Holger SELLNER ,  Nicolas SOLDERMANN ,  Markus VOEGTLE ,  Markus WARTMANN

IPC: A61K31/4155 ,  C07D307/81 ,  C07D405/12 ,  A61K31/343 ,  A61K31/443 ,  A61K31/426 ,  C07D417/04 ,  C07D407/04 ,  A61K31/357 ,  C07D405/04 ,  A61K31/403 ,  A61K31/4525 ,  A61K31/351 ,  C07D407/12 ,  A61K31/506 ,  A61K31/41 ,  A61K31/4025 ,  A61K31/4439 ,  C07D405/14 ,  A61P35/00

Abstract: The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.